Logo image of CV

CAPSOVISION INC (CV) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CV - US1409351079 - Common Stock

12.85 USD
-1.57 (-10.89%)
Last: 12/12/2025, 8:23:19 PM
12.3 USD
-0.55 (-4.28%)
After Hours: 12/12/2025, 8:23:19 PM
Fundamental Rating

3

CV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. While CV has a great health rating, there are worries on its profitability. While showing a medium growth rate, CV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CV has reported negative net income.
CV Yearly Net Income VS EBIT VS OCF VS FCFCV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -147.38%, CV is not doing good in the industry: 87.17% of the companies in the same industry are doing better.
CV has a worse Return On Equity (-185.01%) than 72.19% of its industry peers.
Industry RankSector Rank
ROA -147.38%
ROE -185.01%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CV Yearly ROA, ROE, ROICCV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 -50 -100

1.3 Margins

CV has a Gross Margin (54.21%) which is comparable to the rest of the industry.
The Profit Margin and Operating Margin are not available for CV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CV Yearly Profit, Operating, Gross MarginsCV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

CV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CV remains at a similar level compared to 1 year ago.
There is no outstanding debt for CV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CV Yearly Shares OutstandingCV Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 10M 20M 30M 40M
CV Yearly Total Debt VS Total AssetsCV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 5M 10M 15M 20M

2.2 Solvency

CV has an Altman-Z score of 57.97. This indicates that CV is financially healthy and has little risk of bankruptcy at the moment.
CV has a better Altman-Z score (57.97) than 99.47% of its industry peers.
CV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 57.97
ROIC/WACCN/A
WACC8.83%
CV Yearly LT Debt VS Equity VS FCFCV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 0 10M -10M -20M

2.3 Liquidity

CV has a Current Ratio of 5.19. This indicates that CV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.19, CV is in the better half of the industry, outperforming 78.07% of the companies in the same industry.
A Quick Ratio of 4.50 indicates that CV has no problem at all paying its short term obligations.
CV has a Quick ratio of 4.50. This is amongst the best in the industry. CV outperforms 80.21% of its industry peers.
Industry RankSector Rank
Current Ratio 5.19
Quick Ratio 4.5
CV Yearly Current Assets VS Current LiabilitesCV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CV have decreased strongly by -76.06% in the last year.
Looking at the last year, CV shows a very strong growth in Revenue. The Revenue has grown by 20.54%.
EPS 1Y (TTM)-76.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)20.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CV will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.38% on average per year.
CV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 60.06% yearly.
EPS Next Y-144.67%
EPS Next 2Y-8.41%
EPS Next 3Y14.38%
EPS Next 5YN/A
Revenue Next Year21.95%
Revenue Next 2Y29.78%
Revenue Next 3Y60.06%
Revenue Next 5YN/A

3.3 Evolution

CV Yearly Revenue VS EstimatesCV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 10M 20M 30M 40M
CV Yearly EPS VS EstimatesCV Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CV Price Earnings VS Forward Price EarningsCV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CV Per share dataCV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6 -0.8

4.3 Compensation for Growth

CV's earnings are expected to grow with 14.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.41%
EPS Next 3Y14.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CAPSOVISION INC

NASDAQ:CV (12/12/2025, 8:23:19 PM)

After market: 12.3 -0.55 (-4.28%)

12.85

-1.57 (-10.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)N/A N/A
Inst Owners0.05%
Inst Owner ChangeN/A
Ins Owners17.43%
Ins Owner Change45.14%
Market Cap601.89M
Revenue(TTM)21.39M
Net Income(TTM)-37.82M
Analysts84
Price Target6.12 (-52.37%)
Short Float %0.14%
Short Ratio1.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-857.46%
Min EPS beat(2)-1682.88%
Max EPS beat(2)-32.04%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.09%
Min Revenue beat(2)-6.75%
Max Revenue beat(2)0.58%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)20%
PT rev (3m)9.09%
EPS NQ rev (1m)-16%
EPS NQ rev (3m)-16%
EPS NY rev (1m)-25.93%
EPS NY rev (3m)-53.38%
Revenue NQ rev (1m)-3.38%
Revenue NQ rev (3m)-2.27%
Revenue NY rev (1m)-1.75%
Revenue NY rev (3m)-1.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 28.14
P/FCF N/A
P/OCF N/A
P/B 29.44
P/tB 29.44
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.46
BVpS0.44
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -147.38%
ROE -185.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.21%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.19
Quick Ratio 4.5
Altman-Z 57.97
F-ScoreN/A
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-144.67%
EPS Next 2Y-8.41%
EPS Next 3Y14.38%
EPS Next 5YN/A
Revenue 1Y (TTM)20.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year21.95%
Revenue Next 2Y29.78%
Revenue Next 3Y60.06%
Revenue Next 5YN/A
EBIT growth 1Y-75.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.46%
EBIT Next 3Y13.23%
EBIT Next 5YN/A
FCF growth 1Y-75.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.99%
OCF growth 3YN/A
OCF growth 5YN/A

CAPSOVISION INC / CV FAQ

What is the fundamental rating for CV stock?

ChartMill assigns a fundamental rating of 3 / 10 to CV.


What is the valuation status for CV stock?

ChartMill assigns a valuation rating of 0 / 10 to CAPSOVISION INC (CV). This can be considered as Overvalued.


How profitable is CAPSOVISION INC (CV) stock?

CAPSOVISION INC (CV) has a profitability rating of 0 / 10.


How financially healthy is CAPSOVISION INC?

The financial health rating of CAPSOVISION INC (CV) is 8 / 10.